(Q43035158)

English

Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice

scientific article published on 9 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

author name string

Jie Cao

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Zhihui Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yanli Ren

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Yuan Luo

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Mingmei Cao

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wei Lu

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ping Zhao

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Zhongtian Qi

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

9 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3714-3723

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Global epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

The hepatitis C virus persistence: how to evade the immune system?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Immune responses during acute and chronic infection with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Sequence analysis of the core gene of 14 hepatitis C virus genotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hepatitis C virus core selectively suppresses interleukin-12 synthesis in human macrophages by interfering with AP-1 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

HCV core protein augments cyclosporine immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

gC1qR expression in chimpanzees with resolved and chronic infection: potential role of HCV core/gC1qR-mediated T cell suppression in the outcome of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Efficient induction of mouse immune responses to hepatitis C virus by viral core protein-carrying attenuated Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Neutralizing antibodies in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Development of hepatitis C virus vaccines: challenges and progress.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Biogenesis of hepatitis C virus envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hepatitis C virus cell entry: role of lipoproteins and cellular receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Characterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Vaccination of mice with live recombinant Salmonella typhimurium aroA against H. pylori: parameters associated with prophylactic and therapeutic vaccine efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

A model for the hepatitis C virus envelope glycoprotein E2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Immunization with hepatitis C virus core gene triggers potent T-cell response, but affects CD4+ T-cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Attenuated salmonella and Shigella as carriers for DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Mg2+ as an extracellular signal: environmental regulation of Salmonella virulence.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

An Interplay between Hypervariable Region 1 of the Hepatitis C Virus E2 Glycoprotein, the Scavenger Receptor BI, and High-Density Lipoprotein Promotes both Enhancement of Infection and Protection against Neutralizing Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

Bacterial perturbation of cytokine networks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.083

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2011.02.083

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43035158&oldid=1978266767"